Corporate GovernanceJun 9, 2026, 09:31 AM
Regentis Biomaterials Ltd. Details Director Indemnification and Unregistered Securities Sales
AI Summary
Regentis Biomaterials Ltd. filed an amendment to its registration statement detailing its policies on indemnification, exculpation, and insurance for its office holders, in accordance with Israeli law. The filing also outlines recent sales of unregistered securities, including various convertible and bridge loans that have been amended and, in some cases, converted into ordinary shares. These transactions involved significant amounts and included provisions for risk premiums and warrants tied to an initial public offering.
Key Highlights
- Regentis Biomaterials Ltd. details indemnification and insurance policies for directors, officers, and employees under Israeli Companies Law.
- Company articles of association allow exculpation from liability for breach of duty of care, with limitations.
- Indemnification covers monetary liabilities from judgments, settlements, or awards, and reasonable litigation expenses.
- Insurance can cover breaches of duty of care and monetary liabilities to third parties.
- Exclusions apply for breaches of duty of loyalty, intentional/reckless breaches of care, and unlawful personal benefit.
- Recent sales of unregistered securities include convertible loans and bridge loans totaling significant amounts, with some converting to ordinary shares.
- Various loan agreements were amended to extend maturity dates and include risk premiums and warrants upon IPO.
- The company has entered into underwriting agreements and forms of representative's warrants related to its public offering.
Price Impact
More from RGNT